Header Logo

Connection

Priyabrata Mukherjee to Humans

Back to Details
This is a "connection" page, showing publications Priyabrata Mukherjee has written about Humans.
Priyabrata Mukherjee
Connection Strength
1.241
Humans
  1. Revealing macropinocytosis using nanoparticles. Mol Aspects Med. 2022 02; 83:100993.
    View in: PubMed
    Score: 0.043
  2. MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
    View in: PubMed
    Score: 0.040
  3. Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome. Sci Adv. 2020 07; 6(30):eaba5379.
    View in: PubMed
    Score: 0.040
  4. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer. FASEB J. 2020 09; 34(9):12024-12039.
    View in: PubMed
    Score: 0.040
  5. Cystathionine beta synthase regulates mitochondrial dynamics and function in endothelial cells. FASEB J. 2020 07; 34(7):9372-9392.
    View in: PubMed
    Score: 0.039
  6. Analysing the nanoparticle-protein corona for potential molecular target identification. J Control Release. 2020 06 10; 322:122-136.
    View in: PubMed
    Score: 0.039
  7. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Int J Nanomedicine. 2020; 15:991-1003.
    View in: PubMed
    Score: 0.039
  8. Hydrogen sulfide signaling in mitochondria and disease. FASEB J. 2019 12; 33(12):13098-13125.
    View in: PubMed
    Score: 0.038
  9. Nanoparticle Interactions with the Tumor Microenvironment. Bioconjug Chem. 2019 09 18; 30(9):2247-2263.
    View in: PubMed
    Score: 0.037
  10. Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence. ACS Appl Mater Interfaces. 2019 Jul 24; 11(29):26060-26068.
    View in: PubMed
    Score: 0.037
  11. Gold Nanoparticles Disrupt Tumor Microenvironment - Endothelial Cell Cross Talk To Inhibit Angiogenic Phenotypes in Vitro. Bioconjug Chem. 2019 06 19; 30(6):1724-1733.
    View in: PubMed
    Score: 0.037
  12. Probing Cellular Processes Using Engineered Nanoparticles. Bioconjug Chem. 2018 06 20; 29(6):1793-1808.
    View in: PubMed
    Score: 0.034
  13. Cystathionine ß-synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB J. 2018 08; 32(8):4145-4157.
    View in: PubMed
    Score: 0.034
  14. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.032
  15. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano. 2016 12 27; 10(12):10636-10651.
    View in: PubMed
    Score: 0.031
  16. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84.
    View in: PubMed
    Score: 0.029
  17. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65.
    View in: PubMed
    Score: 0.026
  18. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90.
    View in: PubMed
    Score: 0.026
  19. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
    View in: PubMed
    Score: 0.025
  20. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8.
    View in: PubMed
    Score: 0.024
  21. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5.
    View in: PubMed
    Score: 0.024
  22. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One. 2013; 8(3):e57522.
    View in: PubMed
    Score: 0.024
  23. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650.
    View in: PubMed
    Score: 0.022
  24. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chem Soc Rev. 2012 Apr 07; 41(7):2943-70.
    View in: PubMed
    Score: 0.022
  25. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem. 2011 Dec; 11(10):965-73.
    View in: PubMed
    Score: 0.022
  26. Switching the targeting pathways of a therapeutic antibody by nanodesign. Angew Chem Int Ed Engl. 2012 Feb 13; 51(7):1563-7.
    View in: PubMed
    Score: 0.022
  27. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater. 2011 Nov 16; 23(43):5034-8.
    View in: PubMed
    Score: 0.022
  28. A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity. Chem Commun (Camb). 2011 Aug 14; 47(30):8530-2.
    View in: PubMed
    Score: 0.021
  29. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One. 2011; 6(6):e20347.
    View in: PubMed
    Score: 0.021
  30. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine. 2011 Oct; 7(5):580-7.
    View in: PubMed
    Score: 0.021
  31. Inorganic nanoparticles in cancer therapy. Pharm Res. 2011 Feb; 28(2):237-59.
    View in: PubMed
    Score: 0.020
  32. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A. 2010 Aug 17; 107(33):14541-6.
    View in: PubMed
    Score: 0.020
  33. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010 Jul 14; 10(7):2543-8.
    View in: PubMed
    Score: 0.020
  34. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2010 Mar 08; 62(3):346-61.
    View in: PubMed
    Score: 0.019
  35. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5.
    View in: PubMed
    Score: 0.019
  36. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66.
    View in: PubMed
    Score: 0.018
  37. Biological properties of "naked" metal nanoparticles. Adv Drug Deliv Rev. 2008 Aug 17; 60(11):1289-1306.
    View in: PubMed
    Score: 0.017
  38. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol. 2008; 7(4):313-26.
    View in: PubMed
    Score: 0.017
  39. Antiangiogenic properties of gold nanoparticles. Clin Cancer Res. 2005 May 01; 11(9):3530-4.
    View in: PubMed
    Score: 0.014
  40. Vascular Endothelial Growth Factor as an Immediate-Early Activator of Ultraviolet-Induced Skin Injury. Mayo Clin Proc. 2022 01; 97(1):154-164.
    View in: PubMed
    Score: 0.011
  41. Active Targeting Significantly Outperforms Nanoparticle Size in Facilitating Tumor-Specific Uptake in Orthotopic Pancreatic Cancer. ACS Appl Mater Interfaces. 2021 Oct 27; 13(42):49614-49630.
    View in: PubMed
    Score: 0.011
  42. When the chains do not break: the role of USP10 in physiology and pathology. Cell Death Dis. 2020 12 04; 11(12):1033.
    View in: PubMed
    Score: 0.010
  43. Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses. Brief Bioinform. 2020 07 15; 21(4):1182-1195.
    View in: PubMed
    Score: 0.010
  44. KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
    View in: PubMed
    Score: 0.010
  45. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol. 2019 07; 14(7):629-635.
    View in: PubMed
    Score: 0.009
  46. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 10; 17(10):2136-2143.
    View in: PubMed
    Score: 0.009
  47. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 04 15; 78(8):1923-1934.
    View in: PubMed
    Score: 0.008
  48. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
    View in: PubMed
    Score: 0.008
  49. BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
    View in: PubMed
    Score: 0.008
  50. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 08; 7(45):72845-72859.
    View in: PubMed
    Score: 0.008
  51. Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB J. 2016 12; 30(12):4042-4055.
    View in: PubMed
    Score: 0.008
  52. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93.
    View in: PubMed
    Score: 0.008
  53. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.007
  54. Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells. Apoptosis. 2016 Mar; 21(3):329-39.
    View in: PubMed
    Score: 0.007
  55. Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy. 2016; 12(4):659-70.
    View in: PubMed
    Score: 0.007
  56. Cystathionine ß-synthase regulates endothelial function via protein S-sulfhydration. FASEB J. 2016 Jan; 30(1):441-56.
    View in: PubMed
    Score: 0.007
  57. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.
    View in: PubMed
    Score: 0.005
  58. Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. Nanotechnology. 2010 Jul 30; 21(30):305102.
    View in: PubMed
    Score: 0.005
  59. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res. 2008 Mar 15; 68(6):1970-8.
    View in: PubMed
    Score: 0.004
  60. Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. FASEB J. 2005 Oct; 19(12):1692-4.
    View in: PubMed
    Score: 0.004
  61. Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J Biol Chem. 2005 Aug 12; 280(32):28848-51.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.